News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

F.D.A. Allows First Use of a Novel Cancer Drug

Al's Comment:

 This is very good news.. first we get access to a new class of drugs - PD-1 inhibitors.  Next - the FDA showed that they understand the cancer community's needs and approved this after only a phase 1 trial.  This could open the floodgates for FDA approval of  new cancer treatments as there are a few brain cancer treatments in the pipeline that will soon be reporting phase 2 results. IF the results are good enough, perhaps we can get them approved without having to wait a few more years for phase 3 to complete.

  This also raises the possibility of combinations of treatments such as adding a CTLA-4 inhibitor such as Yervoy and another drug or 2 - perhaps Avastin.

 

 


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html?_r=0


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740